stockrow
Saturday 7 November 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
- EPS
- −77.1%
- Free cash flow
- −201.4%
Quarter to June 2026, against a year earlier
71.42
4.20
+6.25%
Follow MNPR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
33.56 | 56.05 | 51.35 | 56.10 |
+8 more quarters Free account |
Net Debt/EBITDA |
18.27 | 22.82 | 22.81 | 35.10 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.61 | 0.89 | 0.65 | 0.61 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.38) | (0.41) | (0.45) | (0.29) | |
Cash per Share |
15.72 | 16.11 | 18.94 | 20.17 | |
Shareholders Equity per Share |
15.32 | 15.86 | 18.60 | 19.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.32 | 15.86 | 18.60 | 19.87 | |
Free Cash Flow |
(3.25) | (3.47) | (3.37) | (2.09) | |
Working Capital |
130.75 | 135.29 | 137.73 | 141.52 | |
Net Current Asset Value |
130.64 | 135.15 | 137.57 | 141.45 | |
| Other line items | |||||
Quick Ratio |
33.44 | 55.94 | 51.33 | 55.94 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.41) | (0.45) | (0.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.80 | 1.97 | 2.49 | 1.85 | |
Average Assets |
94.42 | 96.53 | 100.50 | 75.13 | |
Average Common Equity |
91.53 | 94.49 | 96.43 | 73.25 |
Columns are period end dates